Rock Springs Capital Management
Latest statistics and disclosures from Rock Springs Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BPMC, UNH, ISRG, NBIX, LLY, and represent 23.58% of Rock Springs Capital Management's stock portfolio.
- Added to shares of these 10 stocks: INSM (+$54M), GPCR (+$26M), JNJ (+$25M), UNH (+$23M), LLY (+$17M), CGEM (+$12M), NUVL (+$9.9M), TVTX (+$8.7M), SWTX (+$7.5M), RARE (+$6.1M).
- Started 8 new stock positions in CATX, ALLK, INSM, APLS, JNJ, KRRO, CGEM, SWTX.
- Reduced shares in these 10 stocks: IMCR (-$66M), Shockwave Med (-$44M), PEN (-$43M), BSX (-$32M), AGIO (-$31M), OLK (-$30M), SGRY (-$29M), IDXX (-$29M), PODD (-$25M), FRPT (-$24M).
- Sold out of its positions in AMLX, CERE, CGON, COLL, IRON, Neurocrine Biosciences Inc Note 2.250 5/1, RPHM, Shockwave Med, SGRY, VKTX. IMTX.
- Rock Springs Capital Management was a net seller of stock by $-388M.
- Rock Springs Capital Management has $3.3B in assets under management (AUM), dropping by -15.65%.
- Central Index Key (CIK): 0001595725
Tip: Access up to 7 years of quarterly data
Positions held by Rock Springs Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rock Springs Capital Management
Rock Springs Capital Management holds 110 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 8.2 | $271M | 2.5M | 107.78 |
|
|
| UnitedHealth (UNH) | 4.2 | $140M | +19% | 275k | 509.26 |
|
| Intuitive Surgical Com New (ISRG) | 4.0 | $133M | 299k | 444.85 |
|
|
| Neurocrine Biosciences (NBIX) | 3.9 | $129M | -10% | 940k | 137.67 |
|
| Eli Lilly & Co. (LLY) | 3.3 | $110M | +17% | 122k | 905.38 |
|
| Argenx Se Sponsored Adr (ARGX) | 3.0 | $99M | 229k | 430.04 |
|
|
| Acadia Healthcare (ACHC) | 2.4 | $80M | 1.2M | 67.54 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 2.4 | $79M | +8% | 1.9M | 41.10 |
|
| Evolent Health Cl A (EVH) | 2.3 | $78M | +2% | 4.1M | 19.12 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.1 | $69M | -14% | 246k | 280.16 |
|
| Boston Scientific Corporation (BSX) | 1.9 | $63M | -33% | 818k | 77.01 |
|
| Freshpet (FRPT) | 1.9 | $62M | -27% | 480k | 129.39 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.8 | $61M | -9% | 250k | 243.00 |
|
| Mirum Pharmaceuticals (MIRM) | 1.8 | $61M | -4% | 1.8M | 34.19 |
|
| Merus N V (MRUS) | 1.8 | $59M | -12% | 1.0M | 59.17 |
|
| IDEXX Laboratories (IDXX) | 1.8 | $58M | -33% | 120k | 487.20 |
|
| Agilon Health (AGL) | 1.8 | $58M | 8.9M | 6.54 |
|
|
| Dex (DXCM) | 1.7 | $57M | -16% | 500k | 113.38 |
|
| Humana (HUM) | 1.7 | $55M | 147k | 373.65 |
|
|
| Insmed Com Par $.01 (INSM) | 1.6 | $54M | NEW | 808k | 67.00 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.6 | $53M | -15% | 1.3M | 41.06 |
|
| Celldex Therapeutics Com New (CLDX) | 1.6 | $52M | 1.4M | 37.01 |
|
|
| Phreesia (PHR) | 1.5 | $51M | +2% | 2.4M | 21.20 |
|
| Edwards Lifesciences (EW) | 1.5 | $51M | -15% | 550k | 92.37 |
|
| Xenon Pharmaceuticals (XENE) | 1.5 | $50M | 1.3M | 38.99 |
|
|
| West Pharmaceutical Services (WST) | 1.4 | $48M | +6% | 146k | 329.39 |
|
| Penumbra (PEN) | 1.4 | $48M | -47% | 265k | 179.97 |
|
| EXACT Sciences Corporation (EXAS) | 1.4 | $46M | +2% | 1.1M | 42.25 |
|
| Agios Pharmaceuticals (AGIO) | 1.4 | $45M | -40% | 1.0M | 43.12 |
|
| Sarepta Therapeutics (SRPT) | 1.4 | $45M | -13% | 284k | 158.00 |
|
| Irhythm Technologies (IRTC) | 1.3 | $43M | 398k | 107.64 |
|
|
| Structure Therapeutics Sponsored Ads Call Option (GPCR) | 1.3 | $42M | +158% | 1.1M | 39.27 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 1.2 | $40M | 290k | 136.38 |
|
|
| Insulet Corporation (PODD) | 1.2 | $39M | -39% | 195k | 201.80 |
|
| Travere Therapeutics (TVTX) | 1.1 | $37M | +30% | 4.5M | 8.22 |
|
| Brooks Automation (AZTA) | 1.1 | $37M | 696k | 52.62 |
|
|
| Revolution Medicines (RVMD) | 1.1 | $37M | +2% | 943k | 38.81 |
|
| Kymera Therapeutics (KYMR) | 1.0 | $35M | -23% | 1.2M | 29.85 |
|
| Mereo Biopharma Group Spon Ads (MREO) | 1.0 | $33M | +14% | 9.3M | 3.60 |
|
| Warby Parker Cl A Com (WRBY) | 1.0 | $33M | 2.1M | 16.06 |
|
|
| Immunovant (IMVT) | 0.9 | $31M | +3% | 1.2M | 26.40 |
|
| Align Technology (ALGN) | 0.9 | $31M | -42% | 128k | 241.43 |
|
| Akero Therapeutics (AKRO) | 0.8 | $25M | -17% | 1.1M | 23.46 |
|
| Johnson & Johnson (JNJ) | 0.7 | $25M | NEW | 170k | 146.16 |
|
| Lifestance Health Group (LFST) | 0.7 | $24M | 4.8M | 4.91 |
|
|
| Zai Lab Adr (ZLAB) | 0.7 | $23M | 1.3M | 17.33 |
|
|
| Pacira Pharmaceuticals (PCRX) | 0.7 | $23M | -25% | 785k | 28.61 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 0.7 | $22M | 506k | 44.29 |
|
|
| BioCryst Pharmaceuticals (BCRX) | 0.7 | $22M | +3% | 3.6M | 6.18 |
|
| Novo-nordisk A S Adr (NVO) | 0.6 | $21M | 148k | 142.74 |
|
|
| Oscar Health Cl A (OSCR) | 0.6 | $20M | -40% | 1.3M | 15.82 |
|
| Nuvalent Inc-a (NUVL) | 0.6 | $19M | +104% | 256k | 75.86 |
|
| Krystal Biotech (KRYS) | 0.6 | $19M | 106k | 183.64 |
|
|
| Inspire Med Sys (INSP) | 0.5 | $17M | 130k | 133.83 |
|
|
| Inozyme Pharma (INZY) | 0.5 | $17M | 3.7M | 4.46 |
|
|
| Dyne Therapeutics (DYN) | 0.5 | $16M | +2% | 461k | 35.29 |
|
| Dynavax Technologies Corp Com New (DVAX) | 0.4 | $15M | -22% | 1.3M | 11.23 |
|
| Pharvaris N V (PHVS) | 0.4 | $14M | 757k | 18.80 |
|
|
| Immunocore Hldgs Ads (IMCR) | 0.4 | $14M | -82% | 419k | 33.89 |
|
| Vera Therapeutics Cl A (VERA) | 0.4 | $14M | +11% | 381k | 36.18 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.4 | $13M | 289k | 44.79 |
|
|
| Prothena Corp SHS (PRTA) | 0.4 | $13M | 625k | 20.64 |
|
|
| Olink Hldg Ab Sponsored Ads (OLK) | 0.4 | $13M | -70% | 500k | 25.48 |
|
| Charles River Laboratories (CRL) | 0.4 | $12M | +24% | 60k | 206.58 |
|
| BioMarin Pharmaceutical (BMRN) | 0.4 | $12M | 151k | 82.33 |
|
|
| Amicus Therapeutics (FOLD) | 0.4 | $12M | +5% | 1.2M | 9.92 |
|
| Nevro (NVRO) | 0.4 | $12M | +29% | 1.4M | 8.42 |
|
| Cullinan Oncology (CGEM) | 0.3 | $12M | NEW | 658k | 17.44 |
|
| Enliven Therapeutics (ELVN) | 0.3 | $10M | 429k | 23.37 |
|
|
| Jasper Therapeutics Com New (JSPR) | 0.3 | $9.2M | 404k | 22.70 |
|
|
| Novavax Com New (NVAX) | 0.3 | $8.5M | +25% | 675k | 12.66 |
|
| Accolade (ACCD) | 0.2 | $8.2M | -35% | 2.3M | 3.58 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 0.2 | $8.0M | 1.5M | 5.44 |
|
|
| Springworks Therapeutics (SWTX) | 0.2 | $7.5M | NEW | 200k | 37.67 |
|
| Neumora Therapeutics (NMRA) | 0.2 | $7.5M | +17% | 760k | 9.83 |
|
| Applied Therapeutics (APLT) | 0.2 | $7.3M | +3% | 1.6M | 4.67 |
|
| Aurinia Pharmaceuticals (AUPH) | 0.2 | $6.7M | +2% | 1.2M | 5.71 |
|
| Mersana Therapeutics (MRSN) | 0.2 | $6.1M | 3.0M | 2.01 |
|
|
| Beam Therapeutics (BEAM) | 0.2 | $5.9M | +69% | 250k | 23.43 |
|
| Acumen Pharmaceuticals (ABOS) | 0.2 | $5.6M | 2.3M | 2.42 |
|
|
| Compass Therapeutics (CMPX) | 0.2 | $5.5M | 5.5M | 1.00 |
|
|
| Apellis Pharmaceuticals (APLS) | 0.2 | $5.4M | NEW | 141k | 38.36 |
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.1 | $4.7M | 9.6M | 0.49 |
|
|
| Fulcrum Therapeutics (FULC) | 0.1 | $4.5M | 728k | 6.20 |
|
|
| Macrogenics (MGNX) | 0.1 | $4.5M | -19% | 1.1M | 4.25 |
|
| Mineralys Therapeutics (MLYS) | 0.1 | $4.4M | -52% | 379k | 11.70 |
|
| Biohaven (BHVN) | 0.1 | $4.4M | 128k | 34.71 |
|
|
| Pliant Therapeutics (PLRX) | 0.1 | $4.1M | 385k | 10.75 |
|
|
| Pulmonx Corp (LUNG) | 0.1 | $4.1M | 652k | 6.34 |
|
|
| Perspective Therapeutics Com New (CATX) | 0.1 | $4.0M | NEW | 401k | 9.97 |
|
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $3.6M | 1.0M | 3.48 |
|
|
| Essa Pharma Com New (EPIX) | 0.1 | $3.6M | 677k | 5.26 |
|
|
| Aclaris Therapeutics (ACRS) | 0.1 | $3.0M | 2.8M | 1.10 |
|
|
| Gossamer Bio (GOSS) | 0.1 | $2.9M | 3.3M | 0.90 |
|
|
| Travere Therapeutics Note 2.500% 9/1 (Principal) | 0.1 | $2.9M | 3.3M | 0.89 |
|
|
| Xilio Therapeutics (XLO) | 0.1 | $2.8M | +108% | 3.0M | 0.95 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.1 | $2.7M | +2% | 788k | 3.42 |
|
| Leap Therapeutics Com New (LPTX) | 0.1 | $2.5M | +38% | 1.3M | 1.96 |
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.1 | $2.4M | 2.4M | 0.97 |
|
|
| Vigil Neuroscience (VIGL) | 0.1 | $1.9M | 472k | 4.00 |
|
|
| Compugen Ord (CGEN) | 0.1 | $1.7M | -23% | 990k | 1.68 |
|
| Spruce Biosciences (SPRB) | 0.0 | $1.4M | 2.6M | 0.52 |
|
|
| Kyverna Therapeutics (KYTX) | 0.0 | $1.3M | 179k | 7.50 |
|
|
| Korro Bio (KRRO) | 0.0 | $1.2M | NEW | 36k | 33.87 |
|
| Allakos (ALLK) | 0.0 | $1.2M | NEW | 1.2M | 1.00 |
|
| Biomea Fusion (BMEA) | 0.0 | $815k | 181k | 4.50 |
|
|
| Vincerx Pharma Com New (VINC) | 0.0 | $722k | 892k | 0.81 |
|
|
| Nevro Corp Note 2.750% 4/0 (Principal) | 0.0 | $483k | 500k | 0.97 |
|
|
| Talphera Com New (TLPH) | 0.0 | $282k | 317k | 0.89 |
|
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $21k | 134k | 0.16 |
|
Past Filings by Rock Springs Capital Management
SEC 13F filings are viewable for Rock Springs Capital Management going back to 2013
- Rock Springs Capital Management 2024 Q2 filed Aug. 14, 2024
- Rock Springs Capital Management 2024 Q1 filed May 15, 2024
- Rock Springs Capital Management 2023 Q3 filed Nov. 14, 2023
- Rock Springs Capital Management 2023 Q2 filed Aug. 14, 2023
- Rock Springs Capital Management 2023 Q1 filed May 15, 2023
- Rock Springs Capital Management 2022 Q4 filed Feb. 14, 2023
- Rock Springs Capital Management 2022 Q3 filed Nov. 14, 2022
- Rock Springs Capital Management 2022 Q2 filed Aug. 15, 2022
- Rock Springs Capital Management 2022 Q1 filed May 16, 2022
- Rock Springs Capital Management 2021 Q4 filed Feb. 14, 2022
- Rock Springs Capital Management 2021 Q3 filed Nov. 15, 2021
- Rock Springs Capital Management 2021 Q2 filed Aug. 16, 2021
- Rock Springs Capital Management 2021 Q1 filed May 17, 2021
- Rock Springs Capital Management 2020 Q4 filed Feb. 16, 2021
- Rock Springs Capital Management 2020 Q3 filed Nov. 16, 2020
- Rock Springs Capital Management 2020 Q2 filed Aug. 14, 2020